化学
激酶
蛋白激酶A
丝裂原活化蛋白激酶
小分子
丝裂原活化蛋白激酶激酶
MAP激酶激酶激酶
细胞生物学
地图2K7
细胞周期蛋白依赖激酶2
生物化学
生物
作者
Jianping Hu,Jieli Wei,Hyerin Yim,Li Wang,Ling Xie,Margaret S. Jin,Md Kabir,Lihuai Qin,Xian Chen,Jing Liu,Jian Jun Jin
标识
DOI:10.1021/acs.jmedchem.0c01609
摘要
Previously, we reported a first-in-class von Hippel–Lindau (VHL)-recruiting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) degrader, MS432. To date, only two MEK1/2 degrader papers have been published and very limited structure–activity relationships (SAR) have been reported. Here, we describe our extensive SAR studies exploring both von Hippel–Lindau (VHL) and cereblon (CRBN) E3 ligase ligands and a variety of linkers, which resulted in two novel, improved VHL-recruiting MEK1/2 degraders, 24 (MS928) and 27 (MS934), and the first CRBN-recruiting MEK1/2 degrader 50 (MS910). These compounds potently and selectively degraded MEK1/2 by hijacking the ubiquitin-proteasome system, inhibited downstream signaling, and suppressed cancer cell proliferation. Furthermore, concurrent inhibition of BRAF or PI3K significantly potentiated the antitumor activity of degrader 27, suggesting that the combination of MEK1/2 degradation with BRAF or PI3K inhibition may provide potential therapeutic benefits. Finally, besides being more potent, degrader 27 displayed improved plasma exposure levels in mice, representing the best MEK1/2 degrader to date for in vivo studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI